Table 1.
Association of the immune-active phenotype with clinicopathological and molecular features of CRC (n = 241).
| Immune-active phenotype |
STAT1 |
IRF-1 |
IRF-5 |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feature | # | p value | OR | 95%CI | p value | OR | 95%CI | p value | OR | 95%CI | p value | OR | 95%CI | |
| Sex | Male | 135 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Female | 85 | 0.037 | 1.80 | 1.037–3.110 | 0.145 | 1.01 | 0.996–1.025 | 0.990 | 1.00 | 0.981–1.019 | 0.873 | 1.00 | 0.968–1.017 | |
| Patient age | < 69 years | 93 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| > 69 years | 126 | 0.154 | 1.49 | 0.862–2.561 | 0.414 | 1.01 | 0.992–1.020 | 0.013 | 1.03 | 1.005–1.045 | 0.427 | 1.01 | 0.991–1.022 | |
| Tumor size (cm) | < 4.56 cm | 33 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| > 4.56 cm | 19 | 0.122 | 0.38 | 0.111–1.296 | 0.618 | 0.99 | 0.965–1.022 | 0.375 | 0.98 | 0.930–1.028 | 0.264 | 0.98 | 0.945–1.016 | |
| Histological subtype | Non-mucinous | 187 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Mucinous | 33 | 0.192 | 1.62 | 0.779–3.453 | 0.964 | 1.00 | 0.980–1.019 | 0.233 | 0.99 | 0.961–1.010 | 0.175 | 1.02 | 0.994–1.036 | |
| Tumor grade | G1–2 | 158 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| G3 | 62 | 0.841 | 1.06 | 0.588–1.918 | 0.365 | 1.01 | 0.992–1.022 | 0.478 | 0.99 | 0.973–1.013 | 0.488 | 1.01 | 0.989–1.023 | |
| Tumor location | Right | 85 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Left | 99 | 0.014 | 0.48 | 0.263–0.859 | 0.013 | 0.98 | 0.964–0.996 | 0.599 | 1.00 | 0.975–1.015 | 0.027 | 0.98 | 0.965–0.998 | |
| pT | pT1–2 | 37 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| pT3–4 | 182 | 0.777 | 0.90 | 0.444–1.835 | 0.511 | 0.99 | 0.976–1.012 | 0.395 | 1.01 | 0.987–1.035 | 0.678 | 1.00 | 0.976–1.016 | |
| pN | pN0 | 90 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| pN1–2 | 130 | 0.716 | 0.90 | 0.527–1.553 | 0.439 | 0.99 | 0.981–1.009 | 0.625 | 1.01 | 0.986–1.024 | 0.327 | 0.99 | 0.977–1.008 | |
| pM | pM0 | 194 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| pM1 | 26 | 0.002 | 0.14 | 0.039–0.471 | 0.006 | 0.95 | 0.918–0.985 | 0.014 | 0.97 | 0.942–0.993 | 0.009 | 0.96 | 0.937–0.991 | |
| Lymphatic invasion | L0 | 47 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| L1–2 | 158 | 0.762 | 0.90 | 0.470–1.737 | 0.271 | 0.99 | 0.974–1.007 | 0.254 | 1.01 | 0.991–1.035 | 0.317 | 0.99 | 0.972–1.009 | |
| Vascular invasion | V0 | 82 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| V1–2 | 125 | 0.235 | 0.71 | 0.407–1.247 | 0.583 | 1.00 | 0.981–1.011 | 0.690 | 1.00 | 0.985–1.023 | 0.229 | 0.99 | 0.974–1.006 | |
| Budding (10-in-10) | Low-grade | 64 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| High-grade | 63 | 0.414 | 0.75 | 0.369–1.508 | 0.843 | 1.00 | 0.980–1.016 | 0.855 | 1.00 | 0.978–1.027 | 0.467 | 0.99 | 0.973–1.012 | |
| Therapy | None | 164 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| Post-surgical | 56 | 0.251 | 0.70 | 0.373–1.294 | 0.886 | 1.00 | 0.983–1.015 | 0.031 | 0.98 | 0.957–0.998 | 0.947 | 1.00 | 0.983–1.018 | |
| MSI status | Low | 165 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| High | 26 | 0.015 | 3.46 | 1.274 | 0.039 | 1.02 | 1.001–1.042 | 0.503 | 0.99 | 0.963–1.019 | 0.742 | 1.00 | 0.972–1.020 | |